Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

Program Description

Myasthenia gravis (MG) is an autoimmune condition characterized by muscle weakness and fatigue, which can affect patients' quality of life. MG typically presents as ocular weakness, with 90% of MG crises or exacerbations occurring within 2 years of initial presentation. Standard treatment approaches incorporate immunosuppressive therapies, including long-term steroid use, but these can lead to treatment complications, and patients may not achieve optimal outcomes with these conventional approaches. New biologics targeting complement, FcRn, and B cells have shown sustained, long-term effects and good safety and tolerability in MG, yet many patients still face access barriers due to high treatment costs that can hinder their effective use. Managed care pharmacists play a crucial role in addressing these challenges by developing evidence-based guidance that supports care tailored to individual patient needs. This webinar will explore how emerging therapies in MG can be incorporated into personalized disease management approaches to minimize the impact of MG exacerbations and hospitalization. Key discussion points such as dosing schedules, disease control, and patient-reported outcomes will inform managed care decision-making regarding health care resource utilization, medical and pharmacy cost considerations, and the integration of emerging agents into the current treatment landscape for MG.

Target audience: Managed Care Pharmacist
Type of activity: Application
Release date: August 29, 2025
Expiration date: August 31, 2026
Time to complete activity: 1.0 hour
Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Examine the pathophysiology and classification of myasthenia gravis (MG) and its impact on patient health and quality of life.

2. Assess the efficacy and safety profiles of novel and emerging targeted therapies for the management of MG.

3. Analyze the economic challenges associated with MG and discuss value-based approaches to improve timely and appropriate access to innovative treatments.